LINCOLN PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of LINCOLN PHARMACEUTICALS have increased by 7.67% YoY .
The Earnings Per Share (EPS) of LINCOLN PHARMACEUTICALS has increased by 6.74 % YoY. |
||
LINCOLN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 531633|NSE : LINCOLN]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹671 Cr | ₹623 Cr | ₹581 Cr | ₹510 Cr | ₹472 Cr |
| Expenses | ₹573 Cr | ₹522 Cr | ₹481 Cr | ₹421 Cr | ₹377 Cr |
| Operating Profit (Excl OI) | ₹98 Cr | ₹101 Cr | ₹100 Cr | ₹89 Cr | ₹95 Cr |
| Other Income | ₹33 Cr | ₹22 Cr | ₹34 Cr | ₹22 Cr | ₹10.00 Cr |
| Interest | ₹1.01 Cr | ₹1.88 Cr | ₹1.47 Cr | ₹2.03 Cr | ₹1.45 Cr |
| Depreciation | ₹15 Cr | ₹13 Cr | ₹11 Cr | ₹9.17 Cr | ₹8.09 Cr |
| Profit Before Tax | ₹116 Cr | ₹109 Cr | ₹122 Cr | ₹100 Cr | ₹96 Cr |
| Profit After Tax | ₹88 Cr | ₹82 Cr | ₹93 Cr | ₹73 Cr | ₹69 Cr |
| Consolidated Net Profit | ₹88 Cr | ₹82 Cr | ₹93 Cr | ₹73 Cr | ₹69 Cr |
| Earnings Per Share (Rs) | ₹43.88 | ₹41.11 | ₹46.58 | ₹36.40 | ₹34.63 |
| PAT Margin (%) | 12.54 | 12.62 | 15.37 | 13.63 | 13.97 |
| ROE(%) | 12.30 | 13.02 | 17.04 | 15.59 | 17.35 |
| ROCE(%) | 16.27 | 17.55 | 22.53 | 21.82 | 24.29 |
| Total Debt/Equity(x) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 1,164.3 Cr |
| Revenue (TTM) | : | ₹ 694.2 Cr |
| Net Profit(TTM) | : | ₹ 96.5 Cr |
| EPS (TTM) | : | ₹ 48.2 |
| P/E (TTM) | : | 12.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LINCOLN PHARMACEUTICALS | -1.4% | -4.7% | 7.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.4% | -6.2% | 11.8% |
| DIVIS LABORATORIES | -3.3% | 1.4% | 57.4% |
| TORRENT PHARMACEUTICALS | -4.5% | -4% | 35.9% |
| CIPLA | -3.6% | -5% | -10.6% |
| DR REDDYS LABORATORIES | -0.2% | 2.5% | -3% |
| MANKIND PHARMA | 2.1% | 7.1% | -0.6% |
| LUPIN | -2.9% | -5.6% | 4.1% |
| ZYDUS LIFESCIENCES | -4.7% | -1.6% | 14.2% |
LINCOLN PHARMACEUTICALS Revenues
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 7.67 % |
| 5 Yr CAGR | 9.19 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹671 Cr | 7.67 | |
| Mar2025 | ₹623 Cr | 7.35 | |
| Mar2024 | ₹581 Cr | 13.76 | |
| Mar2023 | ₹510 Cr | 8.09 | |
| Mar2022 | ₹472 Cr | - | |
LINCOLN PHARMACEUTICALS Operating Profit
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | -3.75 % |
| 5 Yr CAGR | 0.57 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹98 Cr | -3.75 | |
| Mar2025 | ₹101 Cr | 1.58 | |
| Mar2024 | ₹100 Cr | 12.00 | |
| Mar2023 | ₹89 Cr | -6.58 | |
| Mar2022 | ₹95 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -10.57 % |
| 5 Yr CAGR | -7.88 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 14.56% | -10.57 | |
| Mar2025 | 16.28% | -5.40 | |
| Mar2024 | 17.21% | -1.54 | |
| Mar2023 | 17.48% | -13.55 | |
| Mar2022 | 20.22% | - | |
LINCOLN PHARMACEUTICALS Profit After Tax
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 6.74 % |
| 5 Yr CAGR | 6.10 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹88 Cr | 6.74 | |
| Mar2025 | ₹82 Cr | -11.75 | |
| Mar2024 | ₹93 Cr | 27.99 | |
| Mar2023 | ₹73 Cr | 5.11 | |
| Mar2022 | ₹69 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -0.63 % |
| 5 Yr CAGR | -2.66 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 12.54 % | -0.63 | |
| Mar2025 | 12.62 % | -17.89 | |
| Mar2024 | 15.37 % | 12.77 | |
| Mar2023 | 13.63 % | -2.43 | |
| Mar2022 | 13.97 % | - | |
LINCOLN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 6.74 % |
| 5 Yr CAGR | 6.10 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹44 | 6.74 | |
| Mar2025 | ₹41 | -11.74 | |
| Mar2024 | ₹47 | 27.97 | |
| Mar2023 | ₹36 | 5.11 | |
| Mar2022 | ₹35 | - | |
LINCOLN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | -7.29 % |
| 5 Yr CAGR | -9.53 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 16.27% | -7.29 | |
| Mar2025 | 17.55% | -22.10 | |
| Mar2024 | 22.53% | 3.25 | |
| Mar2023 | 21.82% | -10.17 | |
| Mar2022 | 24.29% | - | |
LINCOLN PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹582.2 |
| Current MarketCap | : | ₹ 1,164.3 Cr |
| Updated EOD on | : | Oct 01,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LINCOLN PHARMACEUTICALS | -1.4% |
-4.7% |
7.7% |
| SENSEX | -2.3% |
-6.6% |
-12% |
LINCOLN PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | -3.8% | -3.2% | 12.6% |
No NSE index found
You may also like the below Video Courses
FAQ about LINCOLN PHARMACEUTICALS Financials
How the annual revenues of LINCOLN PHARMACEUTICALS have changed ?
The Revenues of LINCOLN PHARMACEUTICALS have increased by 7.67% YoY .
How the Earnings per Share (EPS) of LINCOLN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of LINCOLN PHARMACEUTICALS has increased by 6.74 % YoY .
Check out Intrinsic Value of Peers of LINCOLN PHARMACEUTICALS
Compare Stock Analytics of Peers of LINCOLN PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
